Cisplatin/carboplatin cross-resistance in ovarian cancer. by Gore, M. E. et al.
Br. J. Cancer (1989), 60, 767-769 © The 1989
Cisplatin/carboplatin cross-resistance in ovarian cancer
M.E. Gore, I. Fryatt, E. Wiltshaw, T. Dawson, B.A. Robinson & A.H. Calvert
Gynaecology Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.
Summary Forty-six patients who were treated with cisplatin or carboplatin for ovarian cancer developed
resistant disease (no change in measurable disease or progressive disease) and 'crossed over' to the other
platinum compound. Three patients (6.5%) responded to this second treatment but these patients had no
survival advantage compared to the non-responders. One responder had progressive disease on cisplatin before
crossing over to carboplatin.
Cisplatin is one of the most active single agents against
carcinoma of the ovary with a response rate in previously
untreated patients of 50-65% (Barker & Wiltshaw, 1981;
Wiltshaw et al., 1986). Carboplatin, an analogue of cisplatin,
appears to be as active in this condition as the parent com-
pound but considerably less toxic (Calvert et al., 1982; Evans
et al., 1983; Wiltshaw, 1985). As with other tumour types the
development of drug resistance is seen in carcinoma of the
ovary (Stanhope et al., 1977) although when cisplatin is given
to patients with alkylator-resistant disease, response rates of
27-55% are reported (Barker & Wiltshaw, 1981; Wiltshaw &
Kroner, 1976; Bruckner et al., 1978). However, patients who
fail to respond to cisplatin at presentation rarely respond to
any chemotherapeutic agent and even further treatment with
a platinum compound at high dosage usually fails (Barker &
Wiltshaw, 1981; Ozols et al., 1985, 1987).
Analogues of cisplatin have been developed in an attempt
not only to lessen the toxicity of the parent compound, but
also to try to overcome the problem of platinum resistance,
which may be present from the outset of the disease, emerge
during its course or be acquired as a result of treatment.
Some analogues of cisplatin are undoubtedly active against
cisplatin-resistant tumours in experimental systems and it
would appear that it is those derivatives possessing either a
1,2-diaminocycloheptane or a 1,2-diaminecyclohexane group
that exhibit this property (Burchenal et al., 1979). One com-
pound in the latter group, 4-carboxyphthalato (1,2-diamino-
cyclohexane) platinum (II), has now entered clinical trial and
there has been one partial response out of eight patients with
ovarian cancer, all of whom had previously received cisplatin
(Kelsen et al., 1983). However, studies with murine tumours
and human xenografts have suggested that tumours resistant
to cisplatin are also resistant to carboplatin (Bradner et al.,
1980; Wolpert-DeFilippes, 1980; Boven et al., 1985). This is
not surprising in view of recent work that shows that cis-
platin and carboplatin have the same mechanism of action
and that the two compounds differ only in the kinetics of
their interaction with DNA (Knox et al., 1986).
We report here our experience of treating patients who
have developed cisplatin- or carboplatin-resistant ovarian
cancer by 'crossing over' to the other platinum compound. In
this way we have investigated the clinical evidence for non-
cross-resistance between these two analogues in epithelial
ovarian cancer.
Patients and methods
Patients
Patients presenting with epithelial ovarian cancer at the
Royal Marsden Hospital have been treated with cisplatin,
either as a single agent or in combination, since April 1973
and carboplatin began to be used in May 1981. Forty-six
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patients who had been treated with cisplatin or carboplatin
exhibited resistant disease while on treatment (no response,
see Assessment of response) and 'crossed over' to the other
platinum compound. Twenty-three patients first received cis-
platin and then crossed over to carboplatin and 23 patients
were treated with carboplatin first and crossed over to cis-
platin. Resistant disease was defined as no change in measur-
able disease after at least two courses of treatment or pro-
gressive disease after one or more courses.
Patients were only included in the study if they had a
histologically confirmed diagnosis ofepithelial ovarian cancer
and the histologic material was reviewed by a pathologist at
the Royal Marsden Hospital. Patients were excluded if: (1)
they crossed over to the other platinum compound because
of toxicity; (2) they had a previous malignancy or a syn-
chronous second primary; (3) treatment alternated between
the two drugs; (4) one course of chemotherapy was given as
the first treatment; (5) less than 50 mg m-2 cisplatin or
300 mg m-2 carboplatin was given as either the first or
second (crossover) treatment; (6) the second (crossover) treat-
ment was with platinum-containing combination chemo-
therapy; (7) there was unassessable disease at the time of the
second (crossover) treatment; (8) there was inadequate
clinical information or follow-up. Patients who were given
platinum-containing combination chemotherapy as their first
treatment were not excluded from the study, but only 2/46
(4%) of all patients fell into this category.
Patients were staged according to the International Federa-
tion of Gynaecology and Obstetrics (FIGO). FIGO stage and
other prognostic variables were analysed and there were no
significant differences between patients who had received cis-
platin first and those treated first with carboplatin (Table I).
Assessment ofresponse
Response to treatment was assessed clinically, radiograph-
ically, ultrasonographically, surgically or by computed tomo-
graphy. Response criteria were as follows: a complete res-
ponse (CR), the complete disappearance of all disease for at
least one month; partial response (PR), a 50% or greater
reduction in the size of all measurable lesions, including the
complete disappearance of all cytologically proven malignant
effusions, for at least one month without the appearance of
any new lesions; no response (NR) included patients who had
a minimal response but failed to achieve the criteria for PR,
those with stable disease and those with progressive disease
(an increase in tumour diameter by 25%). Response to cross-
over treatment was measured in relation to the amount of
disease at the time the crossover treatment started.
Second-look surgery (laparotomy or laparoscopy) was per-
formed after the first treatment on 17/46 (37%) patients and
after the second treatment on 6/46 (13%) patients.
Treatment schedules
Cisplatin 50-120 mg m2 was given as an intravenous infus-
ion in 250 ml normal saline over 1 h in addition to 100 ml of
20% mannitol over half an hour just before the cisplatin
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Table I Prognostic variables
1st 1st
treatment treatment
carboplatin cisplatin Total
Stage
I 0/23 1/23 1/46
II 0/23 2/23 2/46
III 17/23 12/23 29/46
IV 4/23 3/23 7/46
Recurrence 2/23 5/23 7/46
Surgery
Complete 11/23 13/23 24/46
Histology
Mucinous 2/23 5/23 7/46
Serous 15/23 11/23 26/46
Endometrioid 3/23 2/23 5/46
Clear cell 2/23 1/23 3/46
Other 1/23 4/23 5/46
Differentiation
Poorly 19/23 20/23 39/46
Residual disease
Pre-1st treatment
<2 cm 5/23 5/23 10/46
2- cm 7/23 11/23 18/46
>5 cm 11/23 7/23 18/46
Pre-2nd treatment
<2 cm 2/23 3/23 5/46
2-5 cm 5/23 7/23 12/46
>5 cm 16/23 13/23 29/46
Age
<40 years 1/23 3/23 4/46
>40 years 22/23 20/23 42/46
There were no significant differences between any of the patient
groups. Complete surgery: TAH, BSO ± omentectomy.
infusion and intravenous infusion with 31 of normal saline in
24 h before and after the cisplatin. Carboplatin 300-650
mgm-2 was also given as an infusion over 1 h but dissolved
in 500 ml of 5% dextrose and no hydration was given. The
majority of patients were in prospective randomised trials
with standard protocols.
Statistics
Survival analyses were performed using the log rank test and
Kaplan-Meier survival curves. To obtain the significance of
co-factors affecting survival Cox regression was performed by
the method of partial likelihoods. To assess the balance of
known prognostic factors in different groups the x2 test was
used.
Results
The overall response rate (PR and CR) was 6.5% (3/46) after
patients had crossed from one platinum compound to
another following the development of resistant disease. The
patient who had a CR to her second treatment relapsed after
28 months and died 9 months later. The two other res-
ponders both relapsed 4 months after completing treatment,
but one of these patients did have progressive disease on her
first treatment. Table II shows the clinical details of these
three responding patients.
Follow-up and survival was measured from the start of the
second (crossover) agent. The median follow-up of survivors
was 294 days (range 56-1,036) which was greater than the
median survival of the study group as a whole, 237 days
(range 40-1,206). The survival of the three responders (351,
449 and 1,206 days) was greater than that of the non-
responders, 212 days (range 40-726), but this was not
significant. The survival of patients who were treated first
with cisplatin was identical to that of patients treated with
carboplatin (Figure 1). The doses of carboplatin and cisplatin
are shown in Table III. A median of four courses (range
2-6) were given to patients receiving cisplatin first and five
courses (range 2-10) to those who received carboplatin as
their first treatment. A median of two courses (range 1-9)
were given as second treatment to patients who crossed over
from cisplatin to carboplatin and two courses (range 1-6) to
those who crossed over from carboplatin to cisplatin. The
doses and number of courses given to the responders are
shown in Table II.
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Figure 1 Survival of patients first treated with cisplatin and
those first treated with carboplatin. -- first treatment carbo-
platin (23 patients); ----- first treatment cisplatin (23 patients),
X2=0.63, P=0.4.
Table III Thetotalnumberofcoursesgivenateachdoselevelisshown
for the study group as a whole
1st treatment 2nd treatment
Cisplatin (mgm-2)
50-74 3 2
75- 120 20 21
Carboplatin (mgm-2)
300-499 22 23
500-650 1 0
Discussion
Early clinical studies of carboplatin in ovarian cancer sug-
gested that cisplatin and carboplatin may not be totally
cross-resistant. This suggestion was based on a small number
of patients in a phase II study (Evans et al., 1983) and a
preliminary report of a randomised trial of cisplatin versus
Table II Doses and number ofcourses given to those patients who responded to crossing
over from one platinum compound to another
1st treatment 2nd treatment
Dose No. Dose No.
Drug (mgm-2) courses Response Drug (mgm2) courses Response
Carboplatin 350 3 NR (c) Cisplatin 100 2
50 5 PR (s)
Cisplatin 100 5 PD (s) Carboplatin 300 5 PR (s)
Cisplatin 100 5 NR (s) Carboplatin 400 4 CR (c)
s, second-look surgery; c, clinically defined response
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carboplatin in advanced ovarian cancer in which patients
who suffered toxicity, or who did not respond after two
courses of treatment, crossed over to the other platinum
compound (Wiltshaw, 1985). The main aim of the retrospec-
tive analysis presented here was to determine whether or not,
in the light of many more patients having now received both
drugs, there is still clinical evidence for non-cross-resistance
between these two drugs. Our data suggest that there may
not be complete cross-resistance between cisplatin and car-
boplatin in ovarian cancer because one patient with une-
quivocally progressive disease after five courses ofcisplatin at
100 mg m2 had a surgically assessed response to carbo-
platin. However, the number of patients who respond is very
small (6.5%) and therefore probably not ofclinical value and
we could not demonstrate a survival benefit for the res-
ponders.
An evaluation of cross-resistance between two drugs within
a tumour type requires equitoxic doses of the drugs to be
delivered to the cells. Studies have shown that although the
mechanism of action of cisplatin and carboplatin is the same
once the drugs are bound to DNA, the DNA binding
kinetics of these two drugs are very different. Twenty to 40
times more carboplatin than cisplatin is required in cell cul-
ture systems to produce equivalent binding and cytotoxicity
(Knox et al., 1986). These authors have suggested that a
single dose of 400 mg m2 of carboplatin may be less
effective at producing DNA-bound platinum than a single
30 mg m-2 dose of cisplatin. However, it is incorrect to
attempt to calculate equitoxic doses of these two drugs using
a patient's surface area since it is becoming clear that a more
accurate way of obtaining reproduceable area under the con-
centration-time curves for carboplatin is to use the
glomerular filtration rate (Calvert et al., 1987). Thus cal-
culating equitoxic doses of these two platinum compounds in
patients is highly complex since both the DNA binding
kinetics and the pharmacokinetics of the two drugs have to
be taken into consideration. Furthermore, all carboplatin
phase I and phase II data has been based on dosing accord-
ing to surface area and there is as yet no information on
dose-response in ovarian cancer where doses are calculated
according to the glomerular filtration rate.
Drug resistance may be acquired through a variety of
mechanisms including changes in the biochemical phenotype
of the cell. Lewis and colleagues have shown that there is an
increase in reduced glutathione levels and in glutathione-S
transferase and glutathione peroxidase activity in cells lines
derived from a patient with ovarian carcinoma after the
development of cisplatin resistance (Lewis et al., 1988). If
similar changes in this enzyme system were observed after the
development of resistance to carboplatin then it would not be
surprising that these two drugs are cross-resistant.
We can conclude that even if cross-resistance between
cisplatin and carboplatin is occasionally absent in ovarian
cancer, it is such an infrequent event that it is unexploitable
clinically and of no practical value. However, theoretically
the possibility remains that non-cross-resistance may exist
between cisplatin and other analogues.
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